WO2006011631A3 - Thiazole derivatives having vap-1 inhibitory activity - Google Patents
Thiazole derivatives having vap-1 inhibitory activity Download PDFInfo
- Publication number
- WO2006011631A3 WO2006011631A3 PCT/JP2005/014136 JP2005014136W WO2006011631A3 WO 2006011631 A3 WO2006011631 A3 WO 2006011631A3 JP 2005014136 W JP2005014136 W JP 2005014136W WO 2006011631 A3 WO2006011631 A3 WO 2006011631A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vap
- inhibitory activity
- thiazole derivatives
- compound
- pharmaceutically acceptable
- Prior art date
Links
- 101000774560 Crotalus atrox Zinc metalloproteinase-disintegrin-like VAP1 Proteins 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 150000007979 thiazole derivatives Chemical class 0.000 title 1
- 102100027159 Membrane primary amine oxidase Human genes 0.000 abstract 3
- 101710132836 Membrane primary amine oxidase Proteins 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000001344 Macular Edema Diseases 0.000 abstract 1
- 206010025415 Macular oedema Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 201000010230 macular retinal edema Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002575411A CA2575411A1 (en) | 2004-07-27 | 2005-07-27 | Thiazole derivatives having vap-1 inhibitory activity |
EP05768525A EP1786792B1 (en) | 2004-07-27 | 2005-07-27 | Thiazole derivatives having vap-1 inhibitory activity |
JP2007504792A JP4978464B2 (en) | 2004-07-27 | 2005-07-27 | Thiazole derivatives having VAP-1 inhibitor activity |
US11/572,772 US20070254931A1 (en) | 2004-07-27 | 2005-07-27 | Thiazole Derivatives Having Vap-1 Inhibitory Activity |
DE602005013793T DE602005013793D1 (en) | 2004-07-27 | 2005-07-27 | THIAZONE DERIVATIVES WITH VAP-1-HEMMENDER EFFECT |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2004904196 | 2004-07-27 | ||
AU2004904196A AU2004904196A0 (en) | 2004-07-27 | Thiazole Derivatives Having VAP-1 Inhibitory Activity |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006011631A2 WO2006011631A2 (en) | 2006-02-02 |
WO2006011631A3 true WO2006011631A3 (en) | 2006-04-20 |
Family
ID=35734947
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/014136 WO2006011631A2 (en) | 2004-07-27 | 2005-07-27 | Thiazole derivatives having vap-1 inhibitory activity |
Country Status (10)
Country | Link |
---|---|
US (1) | US20070254931A1 (en) |
EP (1) | EP1786792B1 (en) |
JP (1) | JP4978464B2 (en) |
KR (1) | KR20070050932A (en) |
CN (1) | CN101031555A (en) |
AT (1) | ATE427941T1 (en) |
CA (1) | CA2575411A1 (en) |
DE (1) | DE602005013793D1 (en) |
ES (1) | ES2324922T3 (en) |
WO (1) | WO2006011631A2 (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2641734A1 (en) | 2006-02-15 | 2007-08-23 | Abbott Laboratories | Acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome |
WO2007095603A2 (en) * | 2006-02-15 | 2007-08-23 | Abbott Laboratories | Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome |
TW200913999A (en) * | 2007-06-25 | 2009-04-01 | R Tech Ueno Ltd | Composition for eye diseases acompany hypoxia or ischemia |
KR20100096094A (en) * | 2007-10-19 | 2010-09-01 | 가부시키가이샤 아루떼꾸 우에노 | Pharmaceutical composition for treatment of cataract |
US20090170770A1 (en) * | 2007-11-06 | 2009-07-02 | Ali Hafezi-Moghadam | Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap 1) inhibitor |
ES2442298T3 (en) * | 2008-01-18 | 2014-02-11 | Allergan, Inc. | Selective alpha 2 adrenergic agents of subtype and methods to use them |
TWI437986B (en) | 2008-01-31 | 2014-05-21 | R Tech Ueno Ltd | Thiazole derivative and use thereof as vap-1 inhibitor |
TWI490214B (en) * | 2008-05-30 | 2015-07-01 | 艾德克 上野股份有限公司 | Benzene or thiophene derivative and use thereof as vap-1 inhibitor |
BRPI0920237A2 (en) * | 2008-10-21 | 2015-12-29 | Metabolex Inc | aril gpr120 receptor agonists and their respective uses |
UA112154C2 (en) | 2009-09-08 | 2016-08-10 | Біоті Терапіс Корп. | Use of vap-1 inhibitors for treating fibrotic conditions |
FI20115234A0 (en) | 2011-03-08 | 2011-03-08 | Biotie Therapies Corp | New pyridazinone and pyridone compounds |
SG193307A1 (en) * | 2011-03-15 | 2013-10-30 | Astellas Pharma Inc | Guanidine compound |
EP2781521A4 (en) | 2011-10-19 | 2015-03-04 | Kowa Co | Novel spiroindoline compound, and medicinal agent comprising same |
CA2915163A1 (en) | 2013-06-12 | 2014-12-18 | Proximagen Limited | New therapeutic uses of enzyme inhibitors |
WO2015159112A1 (en) | 2014-04-15 | 2015-10-22 | Pécsi Tudományegyetem | Semicarbazide-sensitive amine oxidase inhibitors for use as analgesics in traumatic neuropathy and neurogenic inflammation |
WO2015189534A1 (en) | 2014-06-12 | 2015-12-17 | Proximagen Limited | Vap-1 inhibitors for treating muscular dystrophy |
CN104478828B (en) * | 2014-12-10 | 2016-07-06 | 漳州片仔癀药业股份有限公司 | 2-amino-7-replaces benzothiazole compound and preparation method thereof and purposes |
JOP20200093A1 (en) | 2015-01-09 | 2017-06-16 | Kyowa Kirin Co Ltd | Production method of thiazole derivative |
JP2018076236A (en) | 2015-06-05 | 2018-05-17 | 株式会社アールテック・ウエノ | Pharmaceutical composition for treating cancer |
JP6809464B2 (en) | 2015-08-06 | 2021-01-06 | 宇部興産株式会社 | Substituted guanidine derivative |
EP3386494A1 (en) | 2015-12-07 | 2018-10-17 | Benevolentai Cambridge Limited | Vap-1 inhibitors for treating pain |
AU2017262707B2 (en) * | 2016-05-12 | 2020-11-19 | Boehringer Ingelheim International Gmbh | Pyridinyl derivatives, pharmaceutical compositions and uses thereof as AOC3 inhibitors |
HUE058181T2 (en) | 2016-12-28 | 2022-07-28 | Ube Industries | Substituted guanidine compound |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4511574A (en) * | 1981-01-08 | 1985-04-16 | Mitsui Toatsu Kagaku Kabushiki Kaisha | N-(4-Phenyl-2-thiazolyl)carbamate derivatives |
WO1996030350A1 (en) * | 1995-03-27 | 1996-10-03 | Fujisawa Pharmaceutical Co., Ltd. | Amidine derivatives |
WO2004067521A1 (en) * | 2003-01-27 | 2004-08-12 | Astellas Pharma Inc. | Thiazole derivatives and their use as vap-1 inhibitors |
WO2004087138A1 (en) * | 2003-03-31 | 2004-10-14 | Sucampo Ag | Method for treating vascular hyperpermeable disease |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4699928A (en) * | 1984-07-13 | 1987-10-13 | Merrell Dow Pharmaceuticals Inc. | Fluoroallylamine derivatives |
IT1181871B (en) * | 1985-04-01 | 1987-09-30 | Consiglio Nazionale Ricerche | SELECTIVE INHIBITORS OF BENZYLAMINOXIDE COMPARED TO OTHER AMINOXIDE |
US4650907A (en) * | 1985-12-05 | 1987-03-17 | Merrell Dow Pharmaceuticals Inc. | Nonaromatic fluoroallylamine MAO inhibitors |
US4916151A (en) * | 1985-12-05 | 1990-04-10 | Merrell Dow Pharmaceuticals Inc. | Method of treating parkinson's syndrome |
US4943593A (en) * | 1988-02-25 | 1990-07-24 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US4965288A (en) * | 1988-02-25 | 1990-10-23 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US5021456A (en) * | 1988-02-25 | 1991-06-04 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US5059814A (en) * | 1988-11-30 | 1991-10-22 | The California Institute Of Technology | Winner-take-all circuits for neural computing systems |
JPH0848664A (en) * | 1994-08-05 | 1996-02-20 | Hisamitsu Pharmaceut Co Inc | New guanidinobenzoic acid ester derivative |
WO2002002090A2 (en) * | 2000-07-05 | 2002-01-10 | Biotie Therapies Corp. | Inhibitors of copper-containing amine oxidases |
AU2002214505A1 (en) * | 2000-11-09 | 2002-05-21 | Biovitrum Ab | New use of 4, 5, 6, 7-tetrahydroimidazo-(4,5-c)pyridine derivatives |
CN1933833B (en) * | 2004-03-18 | 2011-09-07 | 株式会社·R-技术上野 | Aqueous composition comprising thiazole derivative |
-
2005
- 2005-07-27 JP JP2007504792A patent/JP4978464B2/en not_active Expired - Fee Related
- 2005-07-27 AT AT05768525T patent/ATE427941T1/en not_active IP Right Cessation
- 2005-07-27 US US11/572,772 patent/US20070254931A1/en not_active Abandoned
- 2005-07-27 CN CNA200580031703XA patent/CN101031555A/en active Pending
- 2005-07-27 WO PCT/JP2005/014136 patent/WO2006011631A2/en active Application Filing
- 2005-07-27 CA CA002575411A patent/CA2575411A1/en not_active Abandoned
- 2005-07-27 DE DE602005013793T patent/DE602005013793D1/en active Active
- 2005-07-27 KR KR1020077004487A patent/KR20070050932A/en not_active Application Discontinuation
- 2005-07-27 EP EP05768525A patent/EP1786792B1/en not_active Not-in-force
- 2005-07-27 ES ES05768525T patent/ES2324922T3/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4511574A (en) * | 1981-01-08 | 1985-04-16 | Mitsui Toatsu Kagaku Kabushiki Kaisha | N-(4-Phenyl-2-thiazolyl)carbamate derivatives |
WO1996030350A1 (en) * | 1995-03-27 | 1996-10-03 | Fujisawa Pharmaceutical Co., Ltd. | Amidine derivatives |
WO2004067521A1 (en) * | 2003-01-27 | 2004-08-12 | Astellas Pharma Inc. | Thiazole derivatives and their use as vap-1 inhibitors |
WO2004087138A1 (en) * | 2003-03-31 | 2004-10-14 | Sucampo Ag | Method for treating vascular hyperpermeable disease |
Non-Patent Citations (1)
Title |
---|
MATTAMMAL M B ET AL: "MASS SPECTROMETRY OF 2,4-SUBSTITUTED CARCINOGENIC THIAZOLES AND THEIR METABOLITES", September 1985, JOURNAL OF HETEROCYCLIC CHEMISTRY, HETEROCORPORATION. PROVO, US, PAGE(S) 1157-1163, ISSN: 0022-152X, XP009010468 * |
Also Published As
Publication number | Publication date |
---|---|
ES2324922T3 (en) | 2009-08-19 |
JP4978464B2 (en) | 2012-07-18 |
EP1786792A2 (en) | 2007-05-23 |
US20070254931A1 (en) | 2007-11-01 |
DE602005013793D1 (en) | 2009-05-20 |
KR20070050932A (en) | 2007-05-16 |
CN101031555A (en) | 2007-09-05 |
JP2008508188A (en) | 2008-03-21 |
ATE427941T1 (en) | 2009-04-15 |
EP1786792B1 (en) | 2009-04-08 |
CA2575411A1 (en) | 2006-02-02 |
WO2006011631A2 (en) | 2006-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006011631A3 (en) | Thiazole derivatives having vap-1 inhibitory activity | |
TW200420549A (en) | Thiazole derivatives | |
WO2005116002A3 (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
EP2639229A3 (en) | Thiazole Derivative and use thereof as VAP-1 Inhibitor | |
MX2007003161A (en) | Triazole derivative or salt thereof. | |
WO2009063202A3 (en) | Use of crth2 antagonist compounds | |
MY148688A (en) | 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors | |
WO2008075068A3 (en) | Acylaminopyrazoles as fgfr inhibitors | |
AU2009258496A8 (en) | Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity | |
WO2006067165A3 (en) | Indolidone derivatives for the treatment or prevention of fibrotic diseases | |
WO2006028269A3 (en) | Thiazole derivatives having vap-1 ihibitory activity | |
WO2005025554A3 (en) | Dipeptidyl peptidase iv inhibitor | |
WO2008054454A3 (en) | Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents | |
WO2005047244A3 (en) | Inhibition of fgfr3 and treatment of multiple myeloma | |
WO2004018419A3 (en) | Benzimidazole quinolinones and uses thereof | |
WO2007082808A3 (en) | Thiazoles as 11 beta-hsd1 inhibitors | |
WO2009005269A3 (en) | Pharmaceutical composition for preventintion and treatment of restenosis comprising isoxazole derivatives | |
WO2010098600A3 (en) | Substituted azole derivatives, pharmaceutical composition containing the derivatives, and method for treating parkinson's disease using the same | |
WO2006124413A3 (en) | Methods for treating drug resistant cancer | |
WO2007024843A3 (en) | Pyrimidinyl-pyrazole inhibitors of aurora kinases | |
WO2004037789A8 (en) | Methylene urea derivatives as raf-kinase inhibitors | |
EP1627635A3 (en) | Benzothiazolium compounds for use in methods of inhibiting NO production and TNF alpha and treating coronaviral infection | |
WO2009041663A1 (en) | Agent for prevention and/or treatment of skin diseases | |
EP2033954A4 (en) | 6-(heterocycle-substituted benzyl)-4-oxoquinoline compound and use of the same as hiv integrase inhibitor | |
WO2006108682A3 (en) | Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use as anti-fungal agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007504792 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11572772 Country of ref document: US Ref document number: 2575411 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005768525 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077004487 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580031703.X Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2005768525 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11572772 Country of ref document: US |